Helicobacter pylori infection
Conditions
Interventions
Group 1:Vonolaxen 20mg Bid + Colloidal Bismuth Pectin 0.2g Bid + Amoxicillin 1g Bid + Furazolidone 100mg tid 14 days
Group 2:Vonolaxine 20mg Bid + Colloidal Bismuth Pectin 0.2g Bid + Amoxicillin 1g Bid + Tetracycline 500mg tid 14 days
Group 3:Vonolax 20mg Bid + Amoxicillin 750mg qid 14 days
Sponsors
Jiangsu Provincial Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 65 years, no gender limit; 2. Positive carbon 13 breath test, confirmed as Hp infection; 3. Failed at least one standard quadruple 14-day course of Helicobacter pylori in the past; 4. The antibiotic susceptibility test of Helicobacter pylori by gastroscope confirmed that metronidazole, clarithromycin and levofloxacin were all resistant; 5. Informed consent, volunteer participation.
Exclusion criteria
Exclusion criteria: 1. Have used probiotics, antibiotics, bismuth-containing drugs (such as bismuth potassium citrate capsules, etc.) within the past 4 weeks or used histamine receptor antagonists within 2 weeks before treatment (such as famotidine, ranitidine, cimetidine and other preparations) and proton pump inhibitors (such as omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole and other preparations); 2. Those who are allergic to the drugs used in the treatment plan: amoxicillin, clarithromycin, esomeprazole enteric-coated tablets, colloidal bismuth pectin, and polyzinc; 3. Gastroscopy excludes patients with acute upper gastrointestinal bleeding, early and advanced cancer of the upper gastrointestinal tract; 4. Pregnant or lactating patients; 5. Patients with serious primary diseases of liver, kidney, heart, brain, lung, endocrine system and hematopoietic system that cannot be effectively controlled; 6. Clinically significant liver and kidney insufficiency (transaminase greater than 1.5 times the upper limit of normal, or serum creatinine greater than the upper limit of normal); 7. Patients with malignant tumors who cannot give fully informed consent due to mental disorders; 8. Those who have participated in other clinical trials within three months before enrollment; 9. Patients judged by the investigator to be unsuitable to participate in clinical trials; other conditions judged by the investigator to be unsuitable for enrollment; 10. Furazolidone or tetracycline has been used in the previous treatment of Helicobacter pylori; 11. Antibiotic susceptibility test culture negative or any resistance to amoxicillin, furazolidone or tetracycline.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori eradication rate at the end of treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| clinical symptom remission rate;Compliance; | — |
Countries
China
Contacts
Public ContactZhang Guoxin
Outcome results
None listed